Clinical Trials on mCRPC (Metastatic Castration-resistant Prostate Cancer) in India

Total 8 results

Astellas Pharma Inc

Completed

A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

Metastatic Castration Resistant Prostate Cancer

India
AstraZeneca

Completed

Retrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant Prostates Cancer (REMPRO)

Metastatic Castration-resistant Prostates Cancer

India, Peru, Saudi Arabia, Egypt, Colombia, Korea, Republic of, Turkey, United Arab Emirates
Bayer

Recruiting

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Non-metastatic Castration-resistant Prostate Cancer

India
AB Science

Completed

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Metastatic Castrate Resistant Prostate Cancer

Italy, Russian Federation, India, Canada, France, Malaysia
Sanofi

Completed

Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer

Prostate Cancer Metastatic

India
AstraZeneca

Recruiting

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01)

Metastatic Castration-Sensitive Prostate Cancer

United States, Canada, Spain, United Kingdom, Italy, Australia, Korea, Republic of, Belgium, Germany, Japan, Peru, France, China, India, Taiwan, Thailand, Austria, Brazil, Turkey, Malaysia, Finland, Netherlands, Chile, Hungary, Poland, Sw...
Sanofi

Completed

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

Prostate Cancer Metastatic

Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czech Republic, Denmark, Finland, Hungary, India, Ireland, Italy, Kazakhstan, Luxembourg, Malaysia, Mexico, Philippines, Poland, Portugal, Romania, Serbia, Singapo... and more
mAbxience Research S.L.
Laboratorio Elea Phoenix S.A.; Libbs Farmacêutica LTDA

Completed

Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients

Metastatic Colorectal Cancer (mCRC)

Argentina, Brazil, India, Spain, Ukraine

Clinical Trials on mCRPC (Metastatic Castration-resistant Prostate Cancer) in India

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations